NASDAQ:ISEE

IVERIC bio Competitors

$5.87
-0.25 (-4.08 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.87
Now: $5.87
$6.15
50-Day Range
$5.73
MA: $6.25
$6.70
52-Week Range
$3.45
Now: $5.87
$7.98
Volume339,745 shs
Average Volume619,081 shs
Market Capitalization$529.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68

Competitors

IVERIC bio (NASDAQ:ISEE) Vs. IGMS, RVNC, DRNA, AXSM, NGM, and MORF

Should you be buying ISEE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IVERIC bio, including IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), and Morphic (MORF).

IGM Biosciences (NASDAQ:IGMS) and IVERIC bio (NASDAQ:ISEE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

IGM Biosciences has a beta of -1.12, meaning that its stock price is 212% less volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Insider and Institutional Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 84.8% of IVERIC bio shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by company insiders. Comparatively, 4.3% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and IVERIC bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
IVERIC bioN/A-45.42%-41.94%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IGM Biosciences and IVERIC bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
IVERIC bio01102.50

IGM Biosciences currently has a consensus price target of $98.8750, suggesting a potential upside of 44.36%. IVERIC bio has a consensus price target of $13.00, suggesting a potential upside of 121.47%. Given IVERIC bio's higher possible upside, analysts plainly believe IVERIC bio is more favorable than IGM Biosciences.

Valuation & Earnings

This table compares IGM Biosciences and IVERIC bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22

IGM Biosciences is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats IVERIC bio on 6 of the 11 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and IVERIC bio (NASDAQ:ISEE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Revance Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 84.8% of IVERIC bio shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by company insiders. Comparatively, 4.3% of IVERIC bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Revance Therapeutics and IVERIC bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
IVERIC bioN/A-45.42%-41.94%

Analyst Recommendations

This is a breakdown of recent recommendations for Revance Therapeutics and IVERIC bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00503.00
IVERIC bio01102.50

Revance Therapeutics currently has a consensus price target of $36.40, suggesting a potential upside of 29.40%. IVERIC bio has a consensus price target of $13.00, suggesting a potential upside of 121.47%. Given IVERIC bio's higher possible upside, analysts plainly believe IVERIC bio is more favorable than Revance Therapeutics.

Earnings and Valuation

This table compares Revance Therapeutics and IVERIC bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22

IVERIC bio has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Summary

IVERIC bio beats Revance Therapeutics on 9 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and IVERIC bio (NASDAQ:ISEE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.8% of IVERIC bio shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of IVERIC bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and IVERIC bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
IVERIC bioN/A-45.42%-41.94%

Analyst Recommendations

This is a breakdown of recent recommendations for Dicerna Pharmaceuticals and IVERIC bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
IVERIC bio01102.50

Dicerna Pharmaceuticals currently has a consensus price target of $37.8333, suggesting a potential upside of 45.01%. IVERIC bio has a consensus price target of $13.00, suggesting a potential upside of 121.47%. Given IVERIC bio's higher possible upside, analysts plainly believe IVERIC bio is more favorable than Dicerna Pharmaceuticals.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and IVERIC bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22

IVERIC bio has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Summary

IVERIC bio beats Dicerna Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

IVERIC bio (NASDAQ:ISEE) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

IVERIC bio has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.

Profitability

This table compares IVERIC bio and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IVERIC bioN/A-45.42%-41.94%
Axsome TherapeuticsN/A-62.33%-47.87%

Insider & Institutional Ownership

84.8% of IVERIC bio shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of IVERIC bio shares are owned by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares IVERIC bio and Axsome Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36

Axsome Therapeutics is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for IVERIC bio and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IVERIC bio01102.50
Axsome Therapeutics101102.83

IVERIC bio presently has a consensus target price of $13.00, suggesting a potential upside of 121.47%. Axsome Therapeutics has a consensus target price of $146.90, suggesting a potential upside of 177.22%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than IVERIC bio.

Summary

IVERIC bio beats Axsome Therapeutics on 6 of the 11 factors compared between the two stocks.

IVERIC bio (NASDAQ:ISEE) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

IVERIC bio has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares IVERIC bio and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IVERIC bioN/A-45.42%-41.94%
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Insider & Institutional Ownership

84.8% of IVERIC bio shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 4.3% of IVERIC bio shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares IVERIC bio and NGM Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92

NGM Biopharmaceuticals has higher revenue and earnings than IVERIC bio. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for IVERIC bio and NGM Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IVERIC bio01102.50
NGM Biopharmaceuticals00523.29

IVERIC bio presently has a consensus target price of $13.00, suggesting a potential upside of 121.47%. NGM Biopharmaceuticals has a consensus target price of $39.1111, suggesting a potential upside of 53.80%. Given IVERIC bio's higher possible upside, research analysts clearly believe IVERIC bio is more favorable than NGM Biopharmaceuticals.

Summary

NGM Biopharmaceuticals beats IVERIC bio on 10 of the 14 factors compared between the two stocks.

IVERIC bio (NASDAQ:ISEE) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Risk and Volatility

IVERIC bio has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares IVERIC bio and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IVERIC bioN/A-45.42%-41.94%
MorphicN/A-36.62%-20.69%

Earnings and Valuation

This table compares IVERIC bio and Morphic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IVERIC bioN/AN/A$-58,860,000.00($1.39)-4.22
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06

Morphic has higher revenue and earnings than IVERIC bio. Morphic is trading at a lower price-to-earnings ratio than IVERIC bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

84.8% of IVERIC bio shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 4.3% of IVERIC bio shares are owned by insiders. Comparatively, 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for IVERIC bio and Morphic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IVERIC bio01102.50
Morphic00203.00

IVERIC bio presently has a consensus target price of $13.00, suggesting a potential upside of 121.47%. Morphic has a consensus target price of $63.3333, suggesting a potential upside of 6.71%. Given IVERIC bio's higher possible upside, equities analysts clearly believe IVERIC bio is more favorable than Morphic.

Summary

Morphic beats IVERIC bio on 7 of the 12 factors compared between the two stocks.


IVERIC bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
High Trading Volume
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.